25 XP   0   0   10

CSL Ltd
Buy, Hold or Sell?

Let's analyse Csl together

PenkeI guess you are interested in CSL Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of CSL Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about CSL Ltd

I send you an email if I find something interesting about CSL Ltd.

Quick analysis of Csl (30 sec.)










What can you expect buying and holding a share of Csl? (30 sec.)

How much money do you get?

How much money do you get?
A$10.24
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
A$86.19
Expected worth in 1 year
A$157.67
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
A$87.44
Return On Investment
31.7%

For what price can you sell your share?

Current Price per Share
A$275.47
Expected price per share
A$229.20 - A$278.75
How sure are you?
50%

1. Valuation of Csl (5 min.)




Live pricePrice per Share (EOD)

A$275.47

Intrinsic Value Per Share

A$35.28 - A$101.01

Total Value Per Share

A$121.47 - A$187.19

2. Growth of Csl (5 min.)




Is Csl growing?

Current yearPrevious yearGrowGrow %
How rich?$26.7b$21.1b$5.5b20.8%

How much money is Csl making?

Current yearPrevious yearGrowGrow %
Making money$3.3b$3.1b$226.9m6.8%
Net Profit Margin17.0%21.5%--

How much money comes from the company's main activities?

3. Financial Health of Csl (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#1 / 1014

Most Revenue
#1 / 1014

Most Profit
#1 / 1014

Most Efficient
#86 / 1014

What can you expect buying and holding a share of Csl? (5 min.)

Welcome investor! Csl's management wants to use your money to grow the business. In return you get a share of Csl.

What can you expect buying and holding a share of Csl?

First you should know what it really means to hold a share of Csl. And how you can make/lose money.

Speculation

The Price per Share of Csl is A$275.47. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Csl.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Csl, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$86.19. Based on the TTM, the Book Value Change Per Share is A$17.87 per quarter. Based on the YOY, the Book Value Change Per Share is A$32.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$3.99 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Csl.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps4.531.6%4.531.6%4.671.7%4.491.6%3.691.3%
Usd Book Value Change Per Share11.484.2%11.484.2%20.667.5%9.383.4%4.931.8%
Usd Dividend Per Share2.560.9%2.560.9%2.150.8%2.040.7%1.790.6%
Usd Total Gains Per Share14.045.1%14.045.1%22.818.3%11.424.1%6.722.4%
Usd Price Per Share178.11-178.11-172.76-171.26-123.89-
Price to Earnings Ratio39.28-39.28-37.03-38.14-32.07-
Price-to-Total Gains Ratio12.69-12.69-7.57-20.97-34.28-
Price to Book Ratio3.22-3.22-3.94-7.42-9.52-
Price-to-Total Gains Ratio12.69-12.69-7.57-20.97-34.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share176.879287
Number of shares5
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share2.562.04
Usd Book Value Change Per Share11.489.38
Usd Total Gains Per Share14.0411.42
Gains per Quarter (5 shares)70.1857.09
Gains per Year (5 shares)280.71228.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
15123027141188218
210245955282375446
3154689833122563674
42059181114163750902
5256114813952049381130
63071377167624511261358
73581607195728513131586
84101836223832615011814
94612066251936716882042
105122295280040818762270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%28.01.02.090.3%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%23.08.00.074.2%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%31.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%29.02.00.093.5%

Fundamentals of Csl

About CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-04-13 10:40:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of CSL Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Csl earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Csl to the Biotechnology industry mean.
  • A Net Profit Margin of 17.0% means that $0.17 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CSL Ltd:

  • The MRQ is 17.0%. The company is making a huge profit. +2
  • The TTM is 17.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ17.0%TTM17.0%0.0%
TTM17.0%YOY21.5%-4.5%
TTM17.0%5Y21.9%-4.9%
5Y21.9%10Y22.3%-0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.0%-196.1%+213.1%
TTM17.0%-211.9%+228.9%
YOY21.5%-277.7%+299.2%
5Y21.9%-432.9%+454.8%
10Y22.3%-599.3%+621.6%
1.1.2. Return on Assets

Shows how efficient Csl is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Csl to the Biotechnology industry mean.
  • 6.1% Return on Assets means that Csl generated $0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CSL Ltd:

  • The MRQ is 6.1%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 6.1%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ6.1%TTM6.1%0.0%
TTM6.1%YOY7.5%-1.4%
TTM6.1%5Y11.5%-5.4%
5Y11.5%10Y14.7%-3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1%-13.3%+19.4%
TTM6.1%-12.7%+18.8%
YOY7.5%-11.8%+19.3%
5Y11.5%-14.0%+25.5%
10Y14.7%-15.9%+30.6%
1.1.3. Return on Equity

Shows how efficient Csl is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Csl to the Biotechnology industry mean.
  • 14.1% Return on Equity means Csl generated $0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CSL Ltd:

  • The MRQ is 14.1%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 14.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ14.1%TTM14.1%0.0%
TTM14.1%YOY14.7%-0.6%
TTM14.1%5Y26.1%-12.0%
5Y26.1%10Y35.5%-9.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.1%-16.9%+31.0%
TTM14.1%-16.0%+30.1%
YOY14.7%-15.1%+29.8%
5Y26.1%-19.7%+45.8%
10Y35.5%-20.5%+56.0%

1.2. Operating Efficiency of CSL Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Csl is operating .

  • Measures how much profit Csl makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Csl to the Biotechnology industry mean.
  • An Operating Margin of 22.3% means the company generated $0.22  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CSL Ltd:

  • The MRQ is 22.3%. The company is operating efficient. +1
  • The TTM is 22.3%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ22.3%TTM22.3%0.0%
TTM22.3%YOY27.2%-5.0%
TTM22.3%5Y27.7%-5.4%
5Y27.7%10Y28.8%-1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ22.3%-290.9%+313.2%
TTM22.3%-224.4%+246.7%
YOY27.2%-288.3%+315.5%
5Y27.7%-479.5%+507.2%
10Y28.8%-625.2%+654.0%
1.2.2. Operating Ratio

Measures how efficient Csl is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.78 means that the operating costs are $0.78 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of CSL Ltd:

  • The MRQ is 0.777. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.777. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.777TTM0.7770.000
TTM0.777YOY0.728+0.050
TTM0.7775Y0.733+0.044
5Y0.73310Y0.757-0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7773.110-2.333
TTM0.7773.266-2.489
YOY0.7283.783-3.055
5Y0.7335.657-4.924
10Y0.7577.783-7.026

1.3. Liquidity of CSL Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Csl is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.01 means the company has $2.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of CSL Ltd:

  • The MRQ is 2.009. The company is able to pay all its short-term debts. +1
  • The TTM is 2.009. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.009TTM2.0090.000
TTM2.009YOY2.316-0.306
TTM2.0095Y2.450-0.440
5Y2.45010Y2.784-0.334
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0093.905-1.896
TTM2.0094.212-2.203
YOY2.3165.337-3.021
5Y2.4506.062-3.612
10Y2.7846.401-3.617
1.3.2. Quick Ratio

Measures if Csl is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Csl to the Biotechnology industry mean.
  • A Quick Ratio of 0.76 means the company can pay off $0.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CSL Ltd:

  • The MRQ is 0.757. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.757. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.757TTM0.7570.000
TTM0.757YOY1.681-0.924
TTM0.7575Y1.187-0.430
5Y1.18710Y1.288-0.101
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7573.572-2.815
TTM0.7574.001-3.244
YOY1.6815.364-3.683
5Y1.1876.009-4.822
10Y1.2886.287-4.999

1.4. Solvency of CSL Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Csl assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Csl to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.51 means that Csl assets are financed with 50.8% credit (debt) and the remaining percentage (100% - 50.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CSL Ltd:

  • The MRQ is 0.508. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.508. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.508TTM0.5080.000
TTM0.508YOY0.486+0.022
TTM0.5085Y0.537-0.029
5Y0.53710Y0.569-0.032
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5080.336+0.172
TTM0.5080.334+0.174
YOY0.4860.271+0.215
5Y0.5370.366+0.171
10Y0.5690.389+0.180
1.4.2. Debt to Equity Ratio

Measures if Csl is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Csl to the Biotechnology industry mean.
  • A Debt to Equity ratio of 116.6% means that company has $1.17 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CSL Ltd:

  • The MRQ is 1.166. The company is able to pay all its debts with equity. +1
  • The TTM is 1.166. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.166TTM1.1660.000
TTM1.166YOY0.945+0.222
TTM1.1665Y1.201-0.035
5Y1.20110Y1.379-0.178
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1660.382+0.784
TTM1.1660.397+0.769
YOY0.9450.341+0.604
5Y1.2010.432+0.769
10Y1.3790.465+0.914

2. Market Valuation of CSL Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Csl generates.

  • Above 15 is considered overpriced but always compare Csl to the Biotechnology industry mean.
  • A PE ratio of 39.28 means the investor is paying $39.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CSL Ltd:

  • The EOD is 39.013. Based on the earnings, the company is overpriced. -1
  • The MRQ is 39.283. Based on the earnings, the company is overpriced. -1
  • The TTM is 39.283. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD39.013MRQ39.283-0.271
MRQ39.283TTM39.2830.000
TTM39.283YOY37.031+2.253
TTM39.2835Y38.142+1.142
5Y38.14210Y32.067+6.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD39.013-2.262+41.275
MRQ39.283-2.599+41.882
TTM39.283-2.674+41.957
YOY37.031-4.133+41.164
5Y38.142-6.258+44.400
10Y32.067-6.171+38.238
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CSL Ltd:

  • The EOD is 38.676. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 38.944. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 38.944. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD38.676MRQ38.944-0.268
MRQ38.944TTM38.9440.000
TTM38.944YOY32.613+6.331
TTM38.9445Y64.973-26.029
5Y64.97310Y54.306+10.667
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD38.676-2.913+41.589
MRQ38.944-3.275+42.219
TTM38.944-3.508+42.452
YOY32.613-5.620+38.233
5Y64.973-8.306+73.279
10Y54.306-8.854+63.160
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Csl is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.22 means the investor is paying $3.22 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of CSL Ltd:

  • The EOD is 3.196. Based on the equity, the company is fair priced.
  • The MRQ is 3.218. Based on the equity, the company is fair priced.
  • The TTM is 3.218. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.196MRQ3.218-0.022
MRQ3.218TTM3.2180.000
TTM3.218YOY3.939-0.720
TTM3.2185Y7.418-4.200
5Y7.41810Y9.517-2.099
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.1961.858+1.338
MRQ3.2182.090+1.128
TTM3.2182.091+1.127
YOY3.9392.866+1.073
5Y7.4183.488+3.930
10Y9.5173.836+5.681
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of CSL Ltd.

3.1. Funds holding CSL Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2020-10-31Vanguard International Stock Index-Total Intl Stock Indx1.50999995-6883873--
2021-01-31Investment Managers Ser Tr-WCM Focused International Growth Fd0.87-3948049--
2020-12-31Europacific Growth Fund0.86-3893001--
2020-12-31Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund0.64-2901422--
2021-02-28iShares Core MSCI EAFE ETF0.45-2048678--
2021-02-28iShares MSCI Eafe ETF0.33000002-1505346--
2021-02-28Fidelity Series International Growth Fund0.29-1311613--
2021-02-28Fidelity International Index Fund0.2-888927--
2021-02-28JP Morgan ETF Tr-BetaBuilders Developed Asia ex-Japan ETF0.19-843766--
2020-10-31Vanguard Intl Equity Index Fds-FTSE All World ex U.S. Index Fund0.18000001-805734--
Total 5.5199999802503040900.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of CSL Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--17.87117.8710%32.179-44%14.608+22%7.683+133%
Book Value Per Share--86.18686.1860%68.315+26%47.660+81%28.891+198%
Current Ratio--2.0092.0090%2.316-13%2.450-18%2.784-28%
Debt To Asset Ratio--0.5080.5080%0.486+5%0.537-5%0.569-11%
Debt To Equity Ratio--1.1661.1660%0.945+23%1.201-3%1.379-15%
Dividend Per Share--3.9873.9870%3.347+19%3.174+26%2.785+43%
Eps--7.0617.0610%7.266-3%6.988+1%5.746+23%
Free Cash Flow Per Share--7.1237.1230%8.250-14%6.787+5%4.943+44%
Free Cash Flow To Equity Per Share--8.5908.5900%32.986-74%10.394-17%5.649+52%
Gross Profit Margin--0.5640.5640%0.691-18%0.650-13%0.603-6%
Intrinsic Value_10Y_max--101.006--------
Intrinsic Value_10Y_min--35.279--------
Intrinsic Value_1Y_max--8.887--------
Intrinsic Value_1Y_min--4.635--------
Intrinsic Value_3Y_max--27.642--------
Intrinsic Value_3Y_min--13.056--------
Intrinsic Value_5Y_max--47.532--------
Intrinsic Value_5Y_min--20.459--------
Market Cap133121701706.240-1%134220423501.000134220423501.0000%130024050027.520+3%128931279260.200+4%93276507751.065+44%
Net Profit Margin--0.1700.1700%0.215-21%0.219-22%0.223-24%
Operating Margin--0.2230.2230%0.272-18%0.277-20%0.288-23%
Operating Ratio--0.7770.7770%0.728+7%0.733+6%0.757+3%
Pb Ratio3.196-1%3.2183.2180%3.939-18%7.418-57%9.517-66%
Pe Ratio39.013-1%39.28339.2830%37.031+6%38.142+3%32.067+23%
Price Per Share275.470-1%277.380277.3800%269.060+3%266.726+4%192.948+44%
Price To Free Cash Flow Ratio38.676-1%38.94438.9440%32.613+19%64.973-40%54.306-28%
Price To Total Gains Ratio12.602-1%12.69012.6900%7.574+68%20.967-39%34.278-63%
Quick Ratio--0.7570.7570%1.681-55%1.187-36%1.288-41%
Return On Assets--0.0610.0610%0.075-19%0.115-47%0.147-58%
Return On Equity--0.1410.1410%0.147-4%0.261-46%0.355-60%
Total Gains Per Share--21.85921.8590%35.526-38%17.781+23%10.468+109%
Usd Book Value--26778294861.67026778294861.6700%21197788578.028+26%14795696014.800+81%8969737351.313+199%
Usd Book Value Change Per Share--11.47511.4750%20.662-44%9.380+22%4.933+133%
Usd Book Value Per Share--55.34055.3400%43.865+26%30.602+81%18.551+198%
Usd Dividend Per Share--2.5602.5600%2.149+19%2.038+26%1.788+43%
Usd Eps--4.5344.5340%4.665-3%4.487+1%3.689+23%
Usd Free Cash Flow--2213013768.1352213013768.1350%2559995956.519-14%2106658010.026+5%1534527980.221+44%
Usd Free Cash Flow Per Share--4.5734.5730%5.297-14%4.358+5%3.174+44%
Usd Free Cash Flow To Equity Per Share--5.5165.5160%21.180-74%6.674-17%3.627+52%
Usd Market Cap85477444665.577-1%86182933929.99286182933929.9920%83488442522.671+3%82786774412.974+4%59892845626.959+44%
Usd Price Per Share176.879-1%178.106178.1060%172.763+3%171.265+4%123.892+44%
Usd Profit--3335877130.8713335877130.8710%3108931983.552+7%2973403905.907+12%2186131614.519+53%
Usd Revenue--19584155673.60519584155673.6050%14468591919.181+35%13979467197.831+40%10080215360.553+94%
Usd Total Gains Per Share--14.03614.0360%22.811-38%11.417+23%6.721+109%
 EOD+4 -4MRQTTM+0 -0YOY+12 -245Y+23 -1310Y+25 -11

4.2. Fundamental Score

Let's check the fundamental score of CSL Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1539.013
Price to Book Ratio (EOD)Between0-13.196
Net Profit Margin (MRQ)Greater than00.170
Operating Margin (MRQ)Greater than00.223
Quick Ratio (MRQ)Greater than10.757
Current Ratio (MRQ)Greater than12.009
Debt to Asset Ratio (MRQ)Less than10.508
Debt to Equity Ratio (MRQ)Less than11.166
Return on Equity (MRQ)Greater than0.150.141
Return on Assets (MRQ)Greater than0.050.061
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of CSL Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose272.750
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-06-302020-06-302021-06-302022-06-302023-06-30
Net Tangible Assets  5,252,7731,579,4146,832,1872,062,4888,894,6759,698,55318,593,228-19,621,046-1,027,818



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets54,434,012
Total Liabilities27,654,173
Total Stockholder Equity23,715,166
 As reported
Total Liabilities 27,654,173
Total Stockholder Equity+ 23,715,166
Total Assets = 54,434,012

Assets

Total Assets54,434,012
Total Current Assets13,909,712
Long-term Assets40,524,300
Total Current Assets
Cash And Cash Equivalents 2,325,546
Short-term Investments 9,000
Net Receivables 2,908,435
Inventory 8,211,523
Other Current Assets 464,208
Total Current Assets  (as reported)13,909,712
Total Current Assets  (calculated)13,918,712
+/- 9,000
Long-term Assets
Property Plant Equipment 14,049,425
Goodwill 12,137,009
Long Term Investments 173,000
Intangible Assets 24,706,678
Long-term Assets Other -12,127,995
Long-term Assets  (as reported)40,524,300
Long-term Assets  (calculated)38,938,117
+/- 1,586,183

Liabilities & Shareholders' Equity

Total Current Liabilities6,922,557
Long-term Liabilities20,731,616
Total Stockholder Equity23,715,166
Total Current Liabilities
Short-term Debt 1,584,917
Short Long Term Debt 964,000
Accounts payable 1,231,879
Other Current Liabilities 3,661,083
Total Current Liabilities  (as reported)6,922,557
Total Current Liabilities  (calculated)7,441,879
+/- 519,322
Long-term Liabilities
Long term Debt Total 11,172,000
Long term Debt 9,564,000
Capital Lease Obligations Min Short Term Debt114,083
Other Liabilities 2,628,000
Long-term Liabilities Other 493,000
Long-term Liabilities  (as reported)20,731,616
Long-term Liabilities  (calculated)23,971,083
+/- 3,239,467
Total Stockholder Equity
Common Stock517,000
Retained Earnings 21,964,997
Accumulated Other Comprehensive Income 1,750,169
Other Stockholders Equity -517,000
Total Stockholder Equity (as reported)23,715,166
Total Stockholder Equity (calculated)23,715,166
+/-0
Other
Capital Stock517,000
Cash and Short Term Investments 2,325,546
Common Stock Shares Outstanding 483,886
Current Deferred Revenue444,678
Liabilities and Stockholders Equity 54,434,012
Net Debt 16,042,966
Net Invested Capital 26,314,000
Net Tangible Assets -660,000
Net Working Capital 4,651,000
Property Plant and Equipment Gross 12,820,000
Short Long Term Debt Total 18,368,512



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-301997-06-301996-06-301995-06-301994-06-301993-06-30
> Total Assets 
229,155
427,907
472,339
474,686
511,118
523,762
561,538
946,479
1,771,810
2,312,122
1,495,525
2,709,471
2,954,140
3,106,280
3,562,081
4,491,886
5,945,391
4,853,647
5,416,494
5,955,441
5,975,500
6,277,700
6,401,000
7,562,700
9,122,700
10,774,500
12,314,400
22,680,465
24,185,015
41,221,552
54,434,012
54,434,01241,221,55224,185,01522,680,46512,314,40010,774,5009,122,7007,562,7006,401,0006,277,7005,975,5005,955,4415,416,4944,853,6475,945,3914,491,8863,562,0813,106,2802,954,1402,709,4711,495,5252,312,1221,771,810946,479561,538523,762511,118474,686472,339427,907229,155
   > Total Current Assets 
106,001
111,426
103,197
119,146
157,993
175,818
194,702
608,804
569,215
738,700
504,944
1,420,342
1,700,104
1,733,101
1,888,119
2,497,705
3,994,131
2,837,850
2,951,972
3,476,677
3,259,300
3,207,600
3,339,100
3,818,000
4,602,100
4,993,700
5,540,100
9,362,672
9,843,090
23,937,614
13,909,712
13,909,71223,937,6149,843,0909,362,6725,540,1004,993,7004,602,1003,818,0003,339,1003,207,6003,259,3003,476,6772,951,9722,837,8503,994,1312,497,7051,888,1191,733,1011,700,1041,420,342504,944738,700569,215608,804194,702175,818157,993119,146103,197111,426106,001
       Cash And Cash Equivalents 
6,437
1,785
751
1,592
1,625
2,621
2,893
376,403
77,348
106,215
56,239
80,329
551,928
559,278
407,326
671,243
2,040,302
850,770
512,369
1,182,123
762,200
608,700
556,800
556,600
844,500
814,700
657,800
1,734,786
2,409,324
15,176,907
2,325,546
2,325,54615,176,9072,409,3241,734,786657,800814,700844,500556,600556,800608,700762,2001,182,123512,369850,7702,040,302671,243407,326559,278551,92880,32956,239106,21577,348376,4032,8932,6211,6251,5927511,7856,437
       Short-term Investments 
0
0
0
0
42,742
39,184
42,691
412,126
60,870
60,446
0
0
0
5,841
504
1,448
689
407
19,230
1,842
500
300
2,600
600
5,200
1,600
400
3,300
4,800
4,200
9,000
9,0004,2004,8003,3004001,6005,2006002,6003005001,84219,2304076891,4485045,84100060,44660,870412,12642,69139,18442,7420000
       Net Receivables 
61,152
72,538
38,027
53,188
85,039
86,424
93,744
113,398
202,275
190,446
114,456
372,084
409,448
419,291
500,582
652,076
693,158
727,807
832,096
762,020
814,800
914,300
958,500
1,042,700
1,107,300
1,365,500
1,704,900
2,314,161
2,195,138
2,200,393
2,908,435
2,908,4352,200,3932,195,1382,314,1611,704,9001,365,5001,107,3001,042,700958,500914,300814,800762,020832,096727,807693,158652,076500,582419,291409,448372,084114,456190,446202,275113,39893,74486,42485,03953,18838,02772,53861,152
       Inventory 
37,437
37,103
64,419
64,366
71,329
86,773
98,065
118,163
281,972
436,109
330,225
945,654
721,767
722,330
956,981
1,146,308
1,228,362
1,236,235
1,556,115
1,496,306
1,639,400
1,644,500
1,755,600
2,152,000
2,575,800
2,692,800
3,038,800
5,097,313
5,035,764
6,301,171
8,211,523
8,211,5236,301,1715,035,7645,097,3133,038,8002,692,8002,575,8002,152,0001,755,6001,644,5001,639,4001,496,3061,556,1151,236,2351,228,3621,146,308956,981722,330721,767945,654330,225436,109281,972118,16398,06586,77371,32964,36664,41937,10337,437
       Other Current Assets 
975
0
0
0
-42,742
-39,184
-42,691
-411,286
7,620
5,930
4,024
22,275
16,961
26,360
22,726
26,630
31,620
22,630
32,161
34,386
42,400
39,800
65,600
66,100
69,300
119,100
138,600
216,412
202,864
259,143
464,208
464,208259,143202,864216,412138,600119,10069,30066,10065,60039,80042,40034,38632,16122,63031,62026,63022,72626,36016,96122,2754,0245,9307,620-411,286-42,691-39,184-42,742000975
   > Long-term Assets 
123,154
316,481
369,142
355,540
353,125
347,944
366,836
337,675
1,202,595
1,573,422
990,580
1,289,128
1,254,037
1,373,179
1,673,963
1,994,181
1,951,260
2,015,797
2,464,522
2,478,765
2,716,200
3,070,100
3,061,900
3,744,700
4,520,600
5,780,800
6,774,300
13,317,792
14,341,925
17,283,938
40,524,300
40,524,30017,283,93814,341,92513,317,7926,774,3005,780,8004,520,6003,744,7003,061,9003,070,1002,716,2002,478,7652,464,5222,015,7971,951,2601,994,1811,673,9631,373,1791,254,0371,289,128990,5801,573,4221,202,595337,675366,836347,944353,125355,540369,142316,481123,154
       Property Plant Equipment 
114,564
306,356
322,103
307,353
294,536
295,950
307,644
313,747
507,898
562,638
362,205
620,157
586,469
605,761
728,494
933,722
966,444
1,026,507
1,290,306
1,393,557
1,587,200
1,831,000
1,841,300
2,389,600
2,942,700
3,551,400
4,484,300
9,158,170
10,037,962
12,082,600
14,049,425
14,049,42512,082,60010,037,9629,158,1704,484,3003,551,4002,942,7002,389,6001,841,3001,831,0001,587,2001,393,5571,290,3061,026,507966,444933,722728,494605,761586,469620,157362,205562,638507,898313,747307,644295,950294,536307,353322,103306,356114,564
       Goodwill 
3,238
3,049
1,816
406
0
0
0
0
672,330
929,153
552,363
549,098
495,851
545,726
556,120
643,430
611,985
613,640
761,676
688,438
687,500
731,100
705,300
674,300
688,300
1,102,000
1,101,800
1,724,328
1,582,551
1,726,605
12,137,009
12,137,0091,726,6051,582,5511,724,3281,101,8001,102,000688,300674,300705,300731,100687,500688,438761,676613,640611,985643,430556,120545,726495,851549,098552,363929,153672,33000004061,8163,0493,238
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
500
3,905
5,070
8,389
14,117
20,691
21,500
402,900
173,000
173,000402,90021,50020,69114,1178,3895,0703,9055001,000000000000000000000000
       Intangible Assets 
0
956
765
574
0
0
0
0
672,330
60,781
50,679
52,080
71,556
63,378
230,644
227,697
174,524
198,422
216,295
184,825
168,200
193,000
221,600
268,300
367,100
700,500
776,500
3,327,524
3,556,044
3,836,399
24,706,678
24,706,6783,836,3993,556,0443,327,524776,500700,500367,100268,300221,600193,000168,200184,825216,295198,422174,524227,697230,64463,37871,55652,08050,67960,781672,33000005747659560
       Other Assets 
0
0
0
0
0
0
0
16,750
16,427
18,814
34,811
88,743
100,766
197,502
0
184,618
230,913
200,469
180,245
205,900
272,100
313,900
282,000
394,000
518,600
420,700
401,800
558,600
0
0
0
000558,600401,800420,700518,600394,000282,000313,900272,100205,900180,245200,469230,913184,6180197,502100,76688,74334,81118,81416,42716,7500000000
> Total Liabilities 
72,328
111,331
141,091
133,130
148,074
133,500
146,616
152,899
895,852
1,038,991
631,243
1,259,406
1,372,330
1,629,748
1,637,697
1,807,138
1,536,559
1,271,279
1,521,532
2,446,937
2,968,700
3,115,700
3,654,100
4,995,500
5,958,900
6,694,600
7,063,100
13,141,322
12,971,562
20,022,541
27,654,173
27,654,17320,022,54112,971,56213,141,3227,063,1006,694,6005,958,9004,995,5003,654,1003,115,7002,968,7002,446,9371,521,5321,271,2791,536,5591,807,1381,637,6971,629,7481,372,3301,259,406631,2431,038,991895,852152,899146,616133,500148,074133,130141,091111,33172,328
   > Total Current Liabilities 
39,533
44,034
55,818
55,962
70,734
76,508
97,383
109,023
281,190
406,810
163,980
488,082
406,195
765,453
676,561
799,795
989,161
668,745
1,011,177
959,228
906,600
845,300
936,100
1,374,400
1,618,100
1,914,700
2,188,200
3,110,385
4,133,999
10,336,945
6,922,557
6,922,55710,336,9454,133,9993,110,3852,188,2001,914,7001,618,1001,374,400936,100845,300906,600959,2281,011,177668,745989,161799,795676,561765,453406,195488,082163,980406,810281,190109,02397,38376,50870,73455,96255,81844,03439,533
       Short-term Debt 
0
0
0
0
42,742
39,184
42,691
412,126
0
0
412
9,297
16,669
344,038
133,287
122,513
268,230
22,083
241,769
171,112
5,700
5,600
3,200
62,300
122,500
225,700
420,600
293,827
631,102
6,535,301
1,584,917
1,584,9176,535,301631,102293,827420,600225,700122,50062,3003,2005,6005,700171,112241,76922,083268,230122,513133,287344,03816,6699,29741200412,12642,69139,18442,7420000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,890,300
2,280,900
80,528
155,226
301,312
595,323
180,679
396,000
4,420,500
964,000
964,0004,420,500396,000180,679595,323301,312155,22680,5282,280,9001,890,300000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
33,610
76,325
104,033
110,744
232,413
146,846
136,089
177,010
160,630
271,835
210,180
244,711
217,900
261,100
213,900
257,800
408,699
399,000
417,400
422,600
665,650
696,637
860,612
1,231,879
1,231,879860,612696,637665,650422,600417,400399,000408,699257,800213,900261,100217,900244,711210,180271,835160,630177,010136,089146,846232,413110,744104,03376,32533,6100000000
       Other Current Liabilities 
30,714
25,390
35,192
35,814
6,801
15,349
28,240
-336,713
204,865
302,777
88,949
316,294
277,557
320,156
393,054
523,600
501,547
468,036
507,869
565,119
639,800
625,800
675,100
1,008,600
1,096,600
1,271,600
2,800
1,782,426
2,389,344
2,749,800
3,661,083
3,661,0832,749,8002,389,3441,782,4262,8001,271,6001,096,6001,008,600675,100625,800639,800565,119507,869468,036501,547523,600393,054320,156277,557316,29488,949302,777204,865-336,71328,24015,3496,80135,81435,19225,39030,714
   > Long-term Liabilities 
32,795
67,297
85,273
77,168
77,340
56,992
49,233
43,876
614,662
632,181
467,263
771,324
966,135
864,295
961,136
1,007,343
547,398
602,533
510,355
1,487,709
2,062,100
2,270,400
2,718,000
3,621,100
4,340,800
4,779,900
4,874,900
10,030,937
8,837,562
9,685,596
20,731,616
20,731,6169,685,5968,837,56210,030,9374,874,9004,779,9004,340,8003,621,1002,718,0002,270,4002,062,1001,487,709510,355602,533547,3981,007,343961,136864,295966,135771,324467,263632,181614,66243,87649,23356,99277,34077,16885,27367,29732,795
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,277,700
3,081,000
3,852,700
4,160,600
4,242,200
4,831,700
5,333,100
5,163,800
11,172,000
11,172,0005,163,8005,333,1004,831,7004,242,2004,160,6003,852,7003,081,0002,277,7000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
31,498
29,926
54,231
77,050
187,868
336,267
507,777
197,052
134,074
184,788
157,930
165,287
239,800
273,900
258,000
440,300
540,100
488,100
619,300
632,700
1,005,200
1,338,900
1,496,500
2,628,000
2,628,0001,496,5001,338,9001,005,200632,700619,300488,100540,100440,300258,000273,900239,800165,287157,930184,788134,074197,052507,777336,267187,86877,05054,23129,92631,4980000000
> Total Stockholder Equity
156,827
316,576
331,248
341,556
363,044
390,262
414,922
793,580
875,958
1,273,131
864,282
1,450,065
1,581,810
1,476,532
1,924,384
2,684,748
4,408,832
3,582,369
3,894,962
3,508,504
3,006,800
3,162,000
2,746,900
2,567,200
3,163,800
4,079,900
5,251,300
9,480,901
11,163,903
21,199,011
23,715,166
23,715,16621,199,01111,163,9039,480,9015,251,3004,079,9003,163,8002,567,2002,746,9003,162,0003,006,8003,508,5043,894,9623,582,3694,408,8322,684,7481,924,3841,476,5321,581,8101,450,065864,2821,273,131875,958793,580414,922390,262363,044341,556331,248316,576156,827
   Common Stock
79,211
130,000
130,000
130,000
130,000
131,261
233,502
591,321
596,407
923,856
630,966
1,050,414
932,560
737,672
868,483
989,597
2,227,626
968,196
271,355
-382,033
-1,978,300
-2,797,800
-3,560,400
-4,213,000
-4,534,300
-4,634,500
-4,603,000
-4,561,000
483,800
483,800
517,000
517,000483,800483,800-4,561,000-4,603,000-4,634,500-4,534,300-4,213,000-3,560,400-2,797,800-1,978,300-382,033271,355968,1962,227,626989,597868,483737,672932,5601,050,414630,966923,856596,407591,321233,502131,261130,000130,000130,000130,00079,211
   Retained Earnings 
57,988
67,732
76,667
88,762
103,764
124,865
144,553
165,881
205,148
279,206
222,287
346,105
696,594
780,242
1,217,370
1,823,640
2,168,940
2,820,364
4,074,235
4,425,671
4,406,800
5,221,500
6,000,800
6,592,300
7,403,900
8,490,200
9,612,300
15,616,993
16,320,613
19,637,025
21,964,997
21,964,99719,637,02516,320,61315,616,9939,612,3008,490,2007,403,9006,592,3006,000,8005,221,5004,406,8004,425,6714,074,2352,820,3642,168,9401,823,6401,217,370780,242696,594346,105222,287279,206205,148165,881144,553124,865103,76488,76276,66767,73257,988
   Accumulated Other Comprehensive Income 
-63,987
-71,315
-93,793
-117,751
-143,226
-169,190
-196,264
-229,931
-281,316
-342,329
11,028
53,546
-47,344
-41,382
-161,468
-128,490
12,266
-206,191
-450,628
-535,133
578,300
738,300
306,500
187,900
294,200
224,200
242,000
-6,136,093
-5,156,710
1,561,986
1,750,169
1,750,1691,561,986-5,156,710-6,136,093242,000224,200294,200187,900306,500738,300578,300-535,133-450,628-206,19112,266-128,490-161,468-41,382-47,34453,54611,028-342,329-281,316-229,931-196,264-169,190-143,226-117,751-93,793-71,315-63,987
   Capital Surplus 0000000000000000000000000000000
   Treasury Stock00000-4,634,500-4,534,300-4,213,000-3,560,400-2,797,800-1,978,300-373,3000000000000000000000
   Other Stockholders Equity 
83,615
190,159
218,374
240,545
272,506
303,326
233,131
266,309
355,719
412,398
0
0
0
0
0
0
0
0
0
0
0
738,300
-3,405,000
-4,184,500
294,200
224,200
-4,603,000
4,561,000
4,504,600
-483,800
-517,000
-517,000-483,8004,504,6004,561,000-4,603,000224,200294,200-4,184,500-3,405,000738,30000000000000412,398355,719266,309233,131303,326272,506240,545218,374190,15983,615



Balance Sheet

Currency in USD. All numbers in thousands.